TLRY - Tilray, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.72 (-2.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close29.01
Bid28.21 x 1400
Ask28.44 x 800
Day's Range28.28 - 29.60
52 Week Range28.28 - 300.00
Avg. Volume1,697,448
Market Cap2.762B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why one investor is still bullish on Tilray as cannabis sector slumps
    Yahoo Finance Video

    Why one investor is still bullish on Tilray as cannabis sector slumps

    The cannabis space has been facing more and more as profitability proves elusive and short-sellers increase their bets against the industry. Yahoo Finance's Zack Guzman & Kristin Myers, along with Independent Women's Forum Board Member and former NY Congresswoman Nan Hayworth discuss with BedRock Founding Partner & Fmr. Founders Fund Partner Geoff Lewis.

  • Weekly Cannabis Stock News: Tilray Nabs a Key EU Shipment Deal
    Motley Fool

    Weekly Cannabis Stock News: Tilray Nabs a Key EU Shipment Deal

    Well, that didn't take long -- the company's recently opened facility in Portugal is about to ship product. Meanwhile, MedMen comes up with its own delivery enhancement.

  • Better Buy: Canopy Growth vs. Tilray
    Motley Fool

    Better Buy: Canopy Growth vs. Tilray

    Which stock wins in a one-on-one matchup between these two leading Canadian cannabis producers?

  • Bernie versus Joe: Who Has a Better Marijuana Campaign?
    Market Realist

    Bernie versus Joe: Who Has a Better Marijuana Campaign?

    Bernie Sanders versus Joe Biden! Who do you think has a better marijuana campaign? The 2020 presidential election is heating up.

  • Tilray (TLRY): The Importance of Global Markets

    Tilray (TLRY): The Importance of Global Markets

    A lot of the Canadian cannabis LPs shunned the U.S. for global markets and the riches of major stock exchanges. The plan hasn’t really played out as the U.S. market surges into the billions and the global markets sputter around. The Tilray (TLRY) medical cannabis export agreement is one of the first signs of real revenues and also a sign of how far the global markets have to still go.Germany To The RescueTilray signed an agreement with Cannamedical Pharma GmbH for an initial supply of $3.3 million in medical cannabis for German patients. Tilray recently completed a 250,000 square feet campus in Portugal to supply European patients such as these in Germany.Cannamedical has a distribution network of 2,500 pharmacies and clinics in Germany. The deal is a wholesale supply and apparently the Germany company will sell the Tilray cannabis under their brands.The company predicted shipping the order in fall 2019. The news is positive for Tilray considering that Q2’19 medical cannabis declined from Q2’18 levels to only $9.1 million. The international medical cannabis was still an after-thought business with sales of only $1.9 million. In essence, Tilray can split this order between Q3 and Q4 and roughly double quarterly international revenues.Medical cannabis typically has higher price points, but the deal is for a wholesale supply, so the financial metrics are very unclear. The Canadian cannabis company doesn’t breakout operations at the international level other than sales amounts.Underwhelming Deal For some reason, the stock jumped 10% on the news of a deal that amounts to a $1.65 million quarterly increase in sales. The number is material to the internal business, but the stock now has a $3 billion market cap on a deal that amounts to minimal revenue gains for a business with $42 million in quarterly sales.Analysts were already forecasting sales to grow roughly $10 million sequentially over the next couple of quarters so this deal may just fold into existing expectations. After all, the Tilray Portugal facility received in May a standard manufacturing license and a GMP certification in accordance with EMA standards to allow export to European medical markets.To support the $3 billion market valuation, investors better hope that more international deals are on the way. Brightfield Group has the Germany medical cannabis market targeted at $2.7 billion by 2023, but all of the major Canadian cannabis players like Canopy Growth (CGC) and Aurora Cannabis (ACB) are already in Germany. Even just 10% market share by Tilray would lead to $270 million in sales in four short years, but the market is highly competitive already.TakeawayThe key investor takeaway is that Tilray and the other large Canadian LPs bet big on the global markets that haven’t paid off yet. The Germany deal for a minimal $3.3 million in cannabis sales actually highlights the problems facing the sector. The company didn’t build up the European facilities such as the Portugal complex for a million-dollar deal, but clearly Tilray doesn’t have any bigger deals to announce.The stock is already giving up the intial stock gains, but any other more material deals in Europe would potentially turnaround the stock from a brutal year.Visit TipRanks’ Trending Stocks page, and find out what companies Wall Street’s top analysts are looking at now.Disclosure: No position.

  • Canopy Growth Stock Is Short on Fundamentals, But High on Potential

    Canopy Growth Stock Is Short on Fundamentals, But High on Potential

    You don't have to look far to see evidence that publicly traded marijuana companies are incredibly volatile. And that assessment is the same for the top players like Canopy Growth (NYSE:CGC). Just in this month alone, Canopy Growth stock has dropped nearly 23%. And since the end of April, shares have shed slightly more than half its market value.Source: Shutterstock Without any hesitation, it's a sickening decline. Just to make matters worse, stakeholders no longer have the buffer that CGC stock was up on a year-to-date basis. At least at the time of writing, that's no longer true. Since January's opening price, the weed company is now looking at a more than 5% loss.As Noel Gallagher formerly of Oasis fame might ask, where did it all go wrong for CGC stock? According to The Motley Fool's Sean Williams, one of the reasons is the company's goodwill.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn a non-financial context, goodwill actually sounds like a good thing. Certainly, we can use more of it, from in our daily interactions all the way up to in the highest political offices. But from an investor's point of view, goodwill doesn't always live up to its linguistic implications.According to an Associated Press report on the subject, goodwill is the premium that companies place on a bought-out organization's actual assets, such as property, plants and equipment. In other words, goodwill represents vague concepts, such as reputation or corporate culture.This premium is fine during a bull market. But to Williams' point, under iffy circumstances, excessive goodwill may lead to a write-down of its assets. And for a pot investment like Canopy Growth stock, a write-down is the last thing it needs. Why Goodwill Isn't So Bad for CGC StockWilliams makes a compelling argument why you should avoid Canopy Growth stock. Although I'm still bullish on weed, I understand where he's coming from. And especially if you're a conservative investor, I would second his assessment. * 10 Marijuana Stocks That Could See 100% Gains, If Not More Moreover, the Associated Press prepared a great argument for why investors should fear blue-chip S&P 500 companies with excessive premiums for intangibles. Back in the summer of 2016, the news agency wrote that goodwill represented $2.5 trillion of the index's balance sheet. For context, that's roughly 12% of U.S. gross domestic product.Thus, we arrive at a logical argument. If excessive goodwill is bad for storied power players, it must be downright terrible for CGC stock. If we're strictly looking at the financials, then of course, you shouldn't expose yourself to Canopy Growth stock.But let's also remind ourselves that legal marijuana isn't exactly logical. More often than not, companies like CGC are narrative-driven affairs fueled by emotions.That's a far different take from S&P 500 organizations. Specifically, the reason why excessive premiums on intangibles are undesirable for blue chips is that their markets are limited. For example, a tech firm can only sell so many computer chips. If such companies take a hit on goodwill, then it may severely impact pre-tax earnings. Unsure of how they will recoup the losses, observing investors may head for the exits.But with Canopy Growth stock, we don't know what the potential limits are. For right now, the actual limits are whatever the Canadian market can support, which admittedly is not much.But what if we have the long-shot event where the U.S. legalizes marijuana at the federal level? I'd say for CGC that at that point, goodwill isn't a liability, it's a bonus. Canopy Growth Stock Is All About the ReachAt the end of the day, here's why Canopy Growth stock and its ilk like Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) have stunk up the markets. They're all reaching for the potential that international markets may provide.For example, Canopy has secured the right to buy Acreage Holdings (OTCMKTS:ACRGF) on a contingency. And that contingency is that the U.S. fully legalizes weed.Will it happen? I think it will, but I don't have a crystal ball. Clearly, most Canadian cannabis companies think so as well, which is why they're positioning themselves for that possibility. When they do this, their acquisitiveness naturally lifts goodwill.If political events don't go according to plan, probably all weed stocks will collapse. But if legalization does pan out -- and there's compelling evidence that it will -- CGC goes to the moon. That's the charm and the pitfall of marijuana.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Canopy Growth Stock Is Short on Fundamentals, But High on Potential appeared first on InvestorPlace.

  • 3 Pot Stocks With a Huge International Presence
    Motley Fool

    3 Pot Stocks With a Huge International Presence

    These marijuana stocks have cultivation, export, or research deals with at least one dozen countries outside of Canada.

  • MedMen Fires Up to Make Marijuana Legal in Florida
    Market Realist

    MedMen Fires Up to Make Marijuana Legal in Florida

    MedMen (MMNFF) (MMEN) closed 1.9% higher on Thursday. The company launched a 2020 ballot initiative called “Make it Legal Florida."

  • HEXO: What Does Jim Cramer Think?
    Market Realist

    HEXO: What Does Jim Cramer Think?

    HEXO reported its third-quarter earnings on June 12. The company reported revenues of $13.0 million, which fell short of analysts’ estimate.

  • Why Tilray, Splunk, and Retrophin Slumped Today
    Motley Fool

    Why Tilray, Splunk, and Retrophin Slumped Today

    Find out how earnings and other factors hit these stocks.

  • When Exactly Will Aurora Cannabis Stock’s Downtrend End?

    When Exactly Will Aurora Cannabis Stock’s Downtrend End?

    Aurora Cannabis (NYSE:ACB) is stuck in a downward trajectory in the stock markets.Source: ElRoi / Weak quarterly earnings from Tilray (NASDAQ:TLRY) and a regulatory violation from CannTrust Holdings (NYSE:CTST) are scaring investors away from the cannabis sector. When Aurora reports its quarterly results on Sept. 15, what should investors expect? Strong Preliminary SalesAurora stock already reflects the upside quarterly results. On Aug. 6, Aurora posted preliminary fiscal fourth-quarter revenue in the range of $100 million CAD to $107 million CAD. This is up sharply higher from last year's $19.1 million in revenue. Fiscal Q4 2019 net cannabis revenue will be in the range of $90 million to $95 million. Every business segment is firing on all cylinders, with activity strong both internationally and in Canada. Medical and consumer markets will be up year-over-year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe fiscal 2019 revenue of between $249 million and $256 million still values Aurora stock at a price-to-sales in the 30 times range. Even though ACB stock fell from the $10 high in March to the $5.80 range recently, the markets expect strong revenue growth. Aurora cannot report any slowdown in sales nor may it miss on output. For Q4, the production available for sale will be in the upper end of the range between 25,000 kilograms and 30,000 kilograms. * 10 Marijuana Stocks to Ride High on the Farm Bill Despite a forecast for exceeding key performance indicators, markets are no longer bidding the stock higher. In the long term, gross margins will rise as will kilograms of cannabis sold. And as cash costs per gram produced falls, the company will earn a profit. For now, Aurora's adjusted EBITDA is not yet positive. Poor results from Tilray are creating an air of caution for Aurora ahead of its earnings report.CannTrust's disclosure of growing in unlicensed rooms shook away the inherent trust investors had for the company and for the sector as a whole. Health Canada is leaving CannTrust in the dark on what happens next. This is frightening. Regulations imposed on other cannabis firms might slow their growth rates. Canopy's Q1 Miss Hurts ACB StockOn Aug. 15, Canopy Growth (NYSE:CGC) reported an EBITDA loss of $92 million CAD in the first quarter. Even though harvest rose 183% quarter-over-quarter and over three-fold year-over-year, losses mounted. But Canopy wrote down a $1.18 billion CAD warrant liability. It has no other big costs ahead and expects to accelerate the rate of output from here.To shore up its balance sheet, Aurora upsized its credit facility by $160 million CAD to $360 million CAD. The company is bolstering its cash reserves to make an acquisition. Its chief financial officer Glen Ibbott said:The upsizing of our credit facility and broadening of the lending syndicate to include additional Schedule 1 Canadian Banks is further recognition that our best-in-class production facilities lead the industry. Access to this non-dilutive capital is a core funding source the company intends to utilize as it further executes on its strategic growth initiatives.As the valuation of other potential takeover targets falls, Aurora is positioned to buy them at a better price. Unfortunately, investors no longer have the patience to reward firms accumulating debt.Conservative investors tired of waiting for profits should avoid Aurora stock -- and cannabis stocks in general. Conversely, those betting on Aurora announcing a partnership with a major S&P 500 company would get rewarded if it happens. In the interim, Aurora Cannabis is working towards positive EBITDA.Last week, Aurora completed its acquisition of Hempco Food and Fiber for just over $60 million CAD. It issued over 2.6 million shares to pay for the deal. My Takeaway on ACB StockShorts have the upper hand on Aurora Cannabis stock for the time being. At a short float of 11%, the stock will not bounce back until sentiment improves. The stock may retest yearly lows in the coming weeks. If that happens, long-time investors will need to decide if they should buy more shares or keep holding it.As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post When Exactly Will Aurora Cannabis Stock's Downtrend End? appeared first on InvestorPlace.

  • Motley Fool

    Tilray Signs Landmark European Shipment Deal

    The company will deliver $3.3 million worth of medical cannabis from its facility in Portugal to Germany.

  • Aurora Cannabis Doubles Down on U.S. CBD Market

    Aurora Cannabis Doubles Down on U.S. CBD Market

    Aurora Cannabis (NYSE:ACB) is continuing to spread its bets across product lines and markets far and wide. With a market cap now standing at $5.9 billion, the Edmonton, Canada-based marijuana stock is the second-largest cannabis company in the sector just behind Canopy Growth (NYSE:CGC) of $9.25 billion.Source: Shutterstock On Monday, Aurora Cannabis announced that it completed its acquisition of Hempco Food and Fiber, a producer of hemp-based fiber and nutritional supplements such as CBD products. The aggressive move into the small but rapidly expanding CBD market will give Aurora a definite leg up into penetrating the U.S. market, where sales are starting to boom.Despite news of the expansion, ACB stock closed down slightly and is now trading at $5.84, well off its 52-week high of $12.52.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCertainly, investors have cooled off to ACB stock since earlier this year with many believing it is still overvalued in comparison to Tilray (NASDAQ:TLRY) or Hexo (NYSE:HEXO). Yet, taking a long-term prospective, ACB may be a solid value play if it gets closer to its 52-week low of $4.58. * 10 Marijuana Stocks That Could See 100% Gains, If Not More Here are three key reasons why ACB is a good long-term play: Aurora Cannabis Has Rock-Bottom Production CostsAurora Cannabis has certainly been on an acquisition binge since it was first founded in 2006. The acquisition of Hempco was just the latest in a string of ACB stock acquiring more production assets, including the takeover last year of CanniMed Therapeutics for $1.1 billion as well as MedReleaf in a $3.2 billion.In fact, since 2016 Aurora has closed on 18 strategic acquisitions across the entire cannabis production value chain. But now, it commands enormous scale, with operations in five continents, 25 countries and 15 global production facilities. By 2020, ACB stock will have put online a production capacity of 625,000 kgs per year. Eventually, Aurora Cannabis estimates that average production costs given their huge economies of scale will fall to be well below $1 per gram. The long-term winners of the pot stock market will likely be those producers who can implement scale in order to minimize production costs. The U.S. CBD Market Is Already Alive and KickingThe most important reason for ACB's acquisition of Hempco may be the U.S. hemp market. After the U.S. legalized hemp last year, various CBD products from hemp are expected to pop up in drug stores from coast to coast.CBD can be found in a wide range of healthcare products, including skin ointment, infused beverages and CBD oil. The U.S. CBD space is heating up, and many major retailers want to get into that market. This month, the grocery chain Kroger (NYSE:KR) announced it would start selling Charlotte Web's (OTCMKTS:CWBHF) hemp products. In fact, Canopy Growth is investing about $150 million in building a hemp industrial park in New York state where CBD is already legalized acquired AgriNextUSA last March specifically to expand hemp production. ACB Stock Owns the Supply Chain and Creates Brand EquityACB may be the leader among marijuana stocks in terms of focusing on the high end of the cannabis market in order to maximize average selling price. Aurora Cannabis stock invests heavily in research and development to create a marketable brand name and valuable intellectual property. Through global expansion, Aurora is is spending to buy its own distribution channels and establish leadership in key international markets. Size and ownership of distribution channels should allow ACB stock to focus on the highest margin products, notably branded medical marijuana.The weeks ahead may certainly see choppy waters for ACB stock. But given its long-term fundamentals, size, scale and investment in brand equity, Aurora Cannabis stock will be a decent long-term value if it gets any cheaper.As of writing, Theodore Kim does not have any position in the above-mentioned stocks. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks That Could See 100% Gains, If Not More * 11 Stocks Under $10 to Buy Now * 6 China Stocks to Buy on the Dip The post Aurora Cannabis Doubles Down on U.S. CBD Market appeared first on InvestorPlace.

  • Why Did Tilray Stock Rise More than 10% Yesterday?
    Market Realist

    Why Did Tilray Stock Rise More than 10% Yesterday?

    Tilray (TLRY) stock rose 10.4% on Wednesday. According to Bloomberg, the company expects to be profitable in Canada in the next quarter or two.

  • Motley Fool

    When Will the Big Canadian Cannabis Producers Become Profitable?

    Hint: Most are years away from delivering consistent profits. But there's one notable exception.

  • Why Investors Should Trade Cautiously With Hexo Stock

    Why Investors Should Trade Cautiously With Hexo Stock

    Ever since it reported quarterly results on June 13, HEXO (NYSE:HEXO) stock continued its downtrend. At a recent price of $4.23, the stock is getting close to falling below the symbolic $1 billion CAD ($750 million) market capitalization. Growing bearishness around cannabis stocks and the uncertainties around the company's growth prospects are hurting HEXO stock. Then, last month, its key brand executive stepped down from the position. What will it take to get investors interested in the company again?Source: Shutterstock On July 18, Hexo's co-founder and chief brand officer, Adam Miron, stepped down from his position. He will retain his seat on the Hexo Board of directors. Miron may have decided to leave the company because of regulator Health Canada slowing the pace of growth in the industry. Excessive regulations and slow decision-making took away the growth momentum for Hexo and the cannabis market in the last year. Sebastien St-Louis, Hexo's co-founder, said just about what you'd expect: "I respect his decision to take on new challenges and focus on his true passion: building."The Hexo stock price is down more than 40% in the past three months, versus the near-25% decline in the cash-heavy exchange-traded fund AdvisorShares Pure Cannabis ETF (NYSEArca:YOLO). Hexo is the fifth-largest equities holding in the marijuana fund's 28 constituents, at 4.72% of the portfolio. YOLO has a ~17% cash position.InvestorPlace - Stock Market News, Stock Advice & Trading Tips New C's in the C-suiteIn its Q3 2019, Hexo added a new COO, Donald Courtney, who has notable experience at Pepsi Bottling Group, Mars, and as head of MedReleaf. Michael Monahan joined the company as its new CFO. His chief responsibility is driving Hexo's global strategy. By expanding outside of the U.S., the company will have less geographic risks and a bigger addressable market. As more countries legalize cannabis, Hexo's addressable market will expand. These additional executive members will lead the 25 PhDs that the company has on staff. * 10 Stocks Under $5 to Buy for Fall Last quarter, Hexo secured around 200,000 kilograms of hemp supply for CBD and non-THC cannabinoid extraction for fiscal 2020. It has a secondary supply agreement of around 60,000 kilograms of hemp that will be supplied in the next two quarters. Hexo is gearing up for upcoming demand in edibles and concentrates, pending legalization in October in Canada. It signed a multi-year extraction agreement with Valens. This will add 30,000 kilograms of output in the first year and 50,000 kilograms of cannabis and hemp biomass in the second year. Collectively, Hexo has a near-term target of having 150,000 kilograms of supply. Greenhouse Helps Double OutputTo date, Hexo sold over 7.5 million grams of adult-use medical cannabis to Canadians. In the last quarter, sales increased 9% to 2,700 adult-use grams and grams equivalent. As its distribution across the Great White North expands, expect sales from this segment growing.Hexo produced ~9.8 tons of dried gram equivalent (9,800 kilograms). Output increased 98% sequentially after yields increased from its 250,000-square-foot B6 greenhouse. It also benefited from the first harvest at its 1-million-square-foot B9 greenhouse.Looking ahead, the company is prepared for the legalization of edibles and concentrates in October 2019. But the big risk here is any Canadian regulatory delays. This would push Hexo's phase two adult-use output into December. To mitigate these risks, the company is developing CBD gummies, a premium vape line, and cannabis-infused beverages in partnership with Truss, its joint venture with Molson Coors Canada that was announced in October 2018. Pricing HeadwindA drop in gross margins is a major risk for Hexo shareholders. Though the company reported a gross margin of 49% on net revenue, it expects price pressures ahead, as CEO St. Louis said on the recent conference call. "We do expect over the next 24 months as there is significant pricing compression that the flower might gradually gross margins towards the 40% level," he told participants. * 10 Undervalued Stocks With Breakout Potential Despite the pricing compression, Hexo expects its introduction of more advanced products will push the gross margin back toward 50%. Hexo Stock Valuation and Your TakeawayHexo will report quarterly results on Sept. 12 after the market closes. Two analysts who cover Hexo stock have a 125% upside target price (per TipRanks). Realistically, number-crunching a fair value on Hexo at this time is difficult (per its revenue is difficult without knowing when the Canadian government will finalize the regulations. Hexo forecast FY2020 revenue of over $400 million CAD, which is multiples bigger than its $15.9 million CAD ($63.9 million CAD annualized) reported in the third quarter.Investors are taking a wait and see approach. As stocks like Tilray (NASDAQ:TLRY) or CannTrust (NASDAQ:CTST) fall, investors want more proof that revenue growth is sustainable and profits are achievable. HEXO stock investors need the market warming up to cannabis stocks again. It must also meet its revenue projections to win back investors.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post Why Investors Should Trade Cautiously With Hexo Stock appeared first on InvestorPlace.

  • This Marijuana Stock Moves To Begin Its European Invasion In Germany
    Investor's Business Daily

    This Marijuana Stock Moves To Begin Its European Invasion In Germany

    Tilray stock got a boost after the firm said its European invasion plans are to begin in Germany. Other marijuana stocks were mixed Wednesday.

  • Bloomberg

    Tilray to Post a Profit in Canada in the ‘Next Quarter or Two,’ CEO Says

    (Bloomberg) -- Tilray Inc. will be profitable in Canada in the “next quarter or two” and in Europe in the next two to three quarters, according to Chief Executive Officer Brendan Kennedy.“We’ll continue to invest in new regions and new countries, but on an existing basis in terms of our existing footprint, we see profitability within the next half year to year,” Kennedy said in an interview on Bloomberg TV.The pot producer’s stock jumped as much as 8.9% following Kennedy’s comments. It had lost 36% over the previous five sessions after Tilray reported a wider-than-expected loss of $17.9 million before interest, taxes, depreciation and amortization.Kennedy said last week that the industry is still in a growth phase and “you’d be constraining yourself if you were focused on profitability at this point.”Investors, however, are increasingly rewarding cannabis companies that turn a profit, or at least show a path to profitability, and punishing those that don’t. Canopy Growth Corp. fell 14% last Thursday after CEO Mark Zekulin said it won’t report a net profit for three to five years.To contact the reporters on this story: Kristine Owram in Toronto at;Ed Hammond in New York at ehammond12@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at, Divya BaljiFor more articles like this, please visit us at©2019 Bloomberg L.P.


    Cannabis Stocks Fall: Tilray Up 10.4%; General Cannabis Off 5.3%

    Cannabis stocks were mixed Wednesday. Among notable stocks in the sector, eight rose while seven fell. Tilray shares rose $3.04, or 10.38%, to $32.34. The company announced it has signed its first agreement to supply cannabis from its facility in Portugal to Germany.

  • 10 Marijuana Stocks That Could See 100% Gains, If Not More

    10 Marijuana Stocks That Could See 100% Gains, If Not More

    The past several months haven't been particularly kind to cannabis stocks, as the hope (and hype) of the long-term potential collides with short-term reality. That is, most of these companies have spent heavily to take the lead in a highly contested race, but don't yet have the scale needed to drive actual profits.That day is still coming, at least for several of the names in the business. The question is, which ones will be left standing, picking up the pieces of an ever-growing industry?Nobody knows for sure; it's unlikely that even the companies' chiefs are entirely convinced themselves they're being built to last. But, with the marijuana industry having only scratched the surface of what it can be, and likely will be, there's little doubt that at least some of these names could double their current values.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Marijuana Stocks to Buy Now Here's a rundown of the top ten cannabis stocks most likely to dish out a triple-digit gain, sooner or later. Canopy Growth (CGC)Source: Shutterstock It's arguably the name that started cannabis-mania, as Canopy Growth (NYSE:CGC) was the first name to attract a major partner's money. In October 2017, booze company Constellation Brands (NYSE:STZ) bought a 10% stake in Canopy Growth, then in August of last year an additional $4 billion investment in CGC stock made Constellation a near-40% stakeholder. The underlying plan was ultimately ensuring access to a supply for the time when a launch of a cannabis-infused beverage made sense.Since then, the relationship became so strained that a frustrated Constellation management team forced Canopy's CEO Bruce Linton out of the role. An aggressive acquisition spree chewed up more money well before it was ready to drive a return on the investment.Still, the dozen or so acquisitions Canopy Growth has made over the course of the past year gives the organization a wide array of horizontally and vertically minded ways to monetize cannabis at some point in the future. Charlotte's Web Holdings (CWBHF)Source: Shutterstock Don't let the OTC listing fool you. With a market cap of nearly $1 billion and $86 million worth of revenue for its past four reported quarters, Charlotte's Web Holdings (OTCMKTS:CWBHF) is a more legitimate company than many of its exchange-listed counterparts. An over-the-counter listing is just less of a hassle.Charlotte's Web Holdings is uniquely positioned. It's not waiting on legalization of recreational marijuana in the U.S. because it doesn't have to. It already offers CBD oil, and capsules, in the United States and can deliver their product -- legally -- in the mail to anywhere in the U.S. * The 10 Best Cheap Stocks to Buy Right Now Perhaps more compelling, Charlotte's Web Holdings is already turning a profit. Granted, it's not a jaw-dropping bottom line. Last quarter's net income was a modest $2.2 million. It's evidence that the business can be profitable though. Net margins should improve as the company scales up. Aurora Cannabis (ACB)Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. But, Aurora Cannabis (NYSE:ACB) is certainly no slouch on that front. It recently closed on the Hempco deal first announced in April, rounding outs rather robust portfolio too.It was self-serving to be sure, but Aurora CEO Terry Booth wasn't off-base when he said of the closed Hempco acquisition "we have assembled a world-class portfolio of high-quality hemp assets that together form the basis of a strong new operating division that will develop CBD-from-hemp around the world."Aurora Cannabis is also an interesting play simply because it's not trying to be all things to all people. Although it's not terribly easy to distinguish just yet, this company is focused more on medical marijuana, and less on recreational usage.It matters. Although it's more difficult, prices and therefore margins are stronger within the medical marijuana market, where Aurora is quickly demonstrating proficiency. GW Pharmaceuticals (GWPH)Source: Shutterstock It's a name that is often left out of the discussion because (1) it's not looking to capitalize on the ongoing legalization of recreational marijuana, and (2) it has been around for years. But GW Pharmaceuticals (NASDAQ:GWPH) has absolutely earned a spot on any list of cannabis stocks positioned to double in the foreseeable future.GW Pharmaceuticals is, as the name suggests, a pharmaceutical developer. It has worked diligently to extract the full health benefits of cannabidiol, or CBD, for prescription use. It convinced the Food and Drug Administration of that potential in June of last year, securing approval for CBD-based Epidiolex as a means of treating seizures … the first CBD-based drug permitted in the U.S. * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The response has been nothing short of incredible. Some observers were expecting Epidiolex to reach a total of $65 million, total, this year. By the end of the second quarter, GW Pharmaceuticals had actually sold $102 million worth of the drug. Hexo (HEXO)Source: Shutterstock It wasn't one of the names batted around a great deal when marijuana stocks were all the rage during the middle of last year. Since then, Hexo (NYSE:HEXO) has managed to make some noise for itself.Hexo, for the unfamiliar, is building itself from the ground up, specifically to cultivate partnerships with bigger players than can carve out market share better than it ever could on its own. It calls it a "hub and spoke" model, where it serves as the hub and supplies cannabis to various partners at the other end of the spoke. There's room for several.It already has one such partner: Molson Coors Brewing (NYSE:TAP) is looking to build a cannabis beverage brand with Hexo. Other partners with other focal points will be added in time.The hard part about the strategy is, Hexo doesn't appear to be in a hurry to execute it. That patience, however, may ultimately be to the company's advantage. Tilray (TLRY)Source: Shutterstock It's curious. The consensus rating on Tilray (NASDAQ:TLRY) shares is only a little better than a 'Hold.' But, the consensus target is a healthy $64.40 per share. That's more than twice the current price of TLRY stock.It's not an unusual nuance within the cannabis industry at this time. Analysts aren't quite sure how to value these names, most of which are startups, and all of which are being lifted at least a little by hype. It's not easy to see the line dividing what's likely, and what's possible.Still, the average target for Tilray shares marks one of the biggest upsides the professionals expect to see come to fruition. * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure Tilray offers a variety of products, including extracts and dried flower, for users seeking THC as well as CBD. It also sells products on five different continents, making it a geographically diverse player. Cara Therapeutics (CARA)Source: Shutterstock As was the case with GW Pharmaceuticals, Cara Therapeutics (NASDAQ:CARA) has largely been omitted from the discussion of cannabis stocks as a whole because it's not a newcomer catering mostly to recreational users. It's still a cannabis name though, or will be, eventually.Cara's claim to fame at this time is a developmental drug currently just referred to as CR845. It's a prospective alternative to opioids, which are effective painkillers, but also highly addictive. CR845 also has absolutely nothing to do with cannabis.Cara Therapeutics' CR701, however, is a prospective painkiller that specifically uses cannabinoid agonists to block the body's pain receptors. While still years away from commercialization, the clinical trial setting certainly legitimizes cannabis as real medicine. OrganiGram Holdings (OGI)Source: Shutterstock If nothing else, OrganiGram Holdings (NASDAQ:OGI) has earned a look because it's one of the few names in the cannabis business that's profitable. Indeed, with its numbers reported in July, it has been profitable for four straight quarters.The underpinnings for that unusual claim in the cannabis realm largely reflects the company's growing acumen. Even though last quarter's cash production costs grew from 65 cents per gram to 95 cents per gram, that's still less than the $1.42 per gram Aurora had to spend to supply itself, or the $1.48 Tilray laid out to grow its own supply. * The 10 Best Marijuana Stocks to Buy Now Still, the big cost jump last quarter? Don't read too much into it. The costs were associated with an experiment designed to further improve yield. It failed, so the company won't be attempting it again. Medipharm Labs (MEDIF)Source: Shutterstock As was the case with Charlotte's Web Holdings, don't be put off by the OTC listing of Medipharm Labs (OTCMKTS:MEDIF). This company is also on firmer footing than many of its exchange-listed rivals, even if most cannabis investors have never heard of it.Medipharm Labs specializes in one narrow sliver of the budding cannabis arena … extraction. Leveraging technology with experience, this company can turn raw marijuana into pure cannabis that meets the exacting standards most CBD suppliers expect in the current, scrutinizing environment.It's still bleeding money in a big way, here at the industry's infancy. Patience is merited though. This year's top line is projected to grow nearly 40%, followed by another 32% revenue leap next year.That still won't be enough to drag Medipharm out of the red, but scale should pay off soon enough. Cronos Group (CRON)Source: Shutterstock Finally, add Cronos Group (NASDAQ:CRON) to your list of cannabis stocks with the potential to double at some point in the future.Cronos Group does a little of everything, from cannabis research to product development consumer sales. It operates three brands: Peace Naturals, Cove and Spinach. And, like Tilray, it has a presence on five different continents.Perhaps the most bullish argument for CRON stock at this time, however, is the recently initiated coverage from Piper Jaffray. Analyst Michael Lavery notes "We expect Cronos to have modest near-term revenues from Canadian cannabis production, but believe it has significant potential growth opportunities with CBD products in the US, including through its pending acquisition of the Lord Jones brand." * 7 Marijuana Penny Stocks That I May Buy Its partnership with Altria Group (NYSE:MO) also bodes well, even if it has accomplished little so far.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post 10 Marijuana Stocks That Could See 100% Gains, If Not More appeared first on InvestorPlace.

  • Motley Fool

    This Pot Stock Is Headed for a Massive Meltdown According to 1 Analyst

    Is a plunge of 85% or more really in store for one of the biggest Canadian cannabis producers?

  • Benzinga

    Tilray Partners With Cannamedical To Export Medical Cannabis To Germany

    Tilray, Inc. (NASDAQ: TLRY) said Wednesday it signed an agreement with Pharma GmbH (Cannamedical) through its subsidiary Tilray Portugal Unipessoal Lda. The initial shipment is going to be the Tilray’s first shipment from its state-of-the-art EU campus in Portugal to Germany, the company said.

  • Tilray signs first deal to supply pot to Europe out of new Portugal facility

    Tilray signs first deal to supply pot to Europe out of new Portugal facility

    Tilray Inc. has signed its first agreement to supply a European Union country with cannabis from its recently opened facility in Portugal, the company announced early Wednesday morning.

  • Pot Entrepreneurs Can Now Get an MBA in Cannabis

    Pot Entrepreneurs Can Now Get an MBA in Cannabis

    USciences says its program is first-of-its-kind and is offered as a track under the specialized pharma and healthcare MBA.


    Tilray Signs First Deal to Sell Cannabis to Germany From Portugal Facility

    Tilray shares were rising Wednesday after the company announced it signed an initial supply agreement to deliver medical cannabis to a German distributor with product sourced from its new grow house in Portugal. The $3.3 million distribution deal is the first that is tied to the company's operations out of Portugal. "This is a significant milestone for Tilray as we ramp up our capacity to serve international markets and generate revenue from our EU campus through the end of 2019," said Tilray CEO Brendan Kennedy.